Informations for option: Primovist 0.25mmol/Ml Solution For Injection, show other option

Select option:

1. Primovist 0.25mmol/Ml Solution For Injection
2. Primovist 0.25mmol/Ml Solution For Injection

Package leaflet: Information for the user

Primovist 0.25 mmol/ml, solution for injection

Gadoxetate disodium

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

R Keep this leaflet. You may need to read it again.

R If you have any further questions, please ask your doctor giving you Primovist (the radiologist) or the hospital/MRI-centre personnel.

R If you get any side effects talk to your doctor or radiologist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1.    What Primovist is and what it is used for

2.    What you need to know before you are given Primovist

3.    How to use Primovist

4.    Possible side effects

5.    How to store Primovist

6.    Contents of the pack and other information

1.    What Primovist is and what it is used for

Primovist is a contrast medium for magnetic resonance imaging (MRI) of the liver. It is used to help detect and diagnose changes that may be found in the liver. Abnormal signs within the liver can be better evaluated (as to number, size, and distribution). Primovist can also help the doctor determine the nature of any abnormalities, thereby increasing the confidence one can have in the diagnosis.

It is provided as a solution for intravenous injection. This medicine is for diagnostic use only.

MRI is a form of medical diagnostic imaging that forms pictures after water molecules have been detected in normal and abnormal tissues. This is done using a complex system of magnets and radiowaves.

2.    What you need to know before you are given Primovist Do not use Primovist

R if you are allergic to gadoxetate disodium or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before you are given Primovist if you R have or have had allergy (e.g. hay fever, hives) or asthma R had a previous reaction to contrast media R have a poor kidney function. The use of some gadolinium-containing contrast agents in patients with these conditions has been associated with a disease called Nephrogenic Systemic Fibrosis (NSF). NSF is a disease involving thickening of the skin and connective tissues. NSF may result in debilitating joint immobility, muscle weakness or impairment of the function of internal organs which may potentially be life threatening R have a serious disease of the heart and blood vessels R have low potassium levels

R or someone in your family, has ever had problems with the electrical rhythm of the heart (long QT syndrome)

R have had changes to the rhythm or rate of your heartbeat after taking medicines

Before you receive Primovist, tell your doctor if any of these applies to you. Your doctor will decide whether the intended examination is possible or not.

R Allergy-like reactions may occur after use of Primovist. Severe reactions are possible. Delayed reactions may occur (after hours or days) (see section 4 “Possible Side Effects”).

R Tell your doctor if you have a heart pacemaker or if there are any implants or clips containing iron in your body.

Tell your doctor if:

R your kidneys do not work properly

R you have recently had, or soon expect to have, a liver transplant

Your doctor may decide to take a blood test to check how well your kidneys are working before making the decision to use Primovist, especially if you are 65 years of age or older.

Children and adolescents

The safety of Primovist in persons under 18 years has not yet been tested. Therefore, use of Primovist in this patient group cannot be recommended.

Other medicines and Primovist

Tell your doctor if you are taking, have recently taken or might take any other medicines. These include especially:

R betablockers, medicines used to treat high blood pressure or other heart conditions

R medicines that change the rhythm or rate of your heartbeat (e.g. amiodarone, sotalol)

R rifampicin (medicines used to treat tuberculosis).

Pregnancy and breast-feeding Pregnancy

You must tell your doctor if you think you are or might become pregnant as Primovist should not be used during pregnancy unless strictly necessary.

Breast-feeding

Tell your doctor if you are breast-feeding or about to start breastfeeding. Your doctor will discuss whether you should continue breast-feeding or interrupt breast-feeding for a period of 24 hours after you receive Primovist.

Primovist contains sodium

Primovist contains 82 mg of sodium per dose (based on the average amount given to a 70 kg person). This should be taken into consideration if you are on a sodium controlled diet.

3.    How to use Primovist

Primovist is injected by a doctor via a small needle into a vein. Primovist will be administered immediately before your MRI examination.

After the injection you will be observed for at least 30 minutes.

The recommended dose

The actual dosage of Primovist that is right for you will depend on your body weight:

0.1 ml Primovist per kg body weight.

Dosage in special patient groups

The use of Primovist is not recommended in patients with severe kidney problems and patients who have recently had, or soon expect to have, a liver transplant. However if use is required you should only receive one dose of Primovist during a scan and you should not receive a second injection for at least 7 days.

Elderly

It is not necessary to adjust your dose if you are 65 years of age or older but you may have a blood test to check how well your kidneys are working.

Further information regarding the administration and handling of Primovist is given at the end of the leaflet.

If you receive more Primovist than you should

Overdosing is unlikely. If it does happen, the doctor will treat any symptoms that follow.

4.    Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Most of the side effects are mild to moderate.

The most frequently observed side effects in patients receiving Primovist (may affect 5 or more in 1,000 users) are nausea (feeling sick), headache, feeling hot, increased blood pressure, back pain and dizziness.

The most serious side effect in patients receiving Primovist is anaphylactoid shock (a severe allergy-like reaction).

As with other contrast media, in rare cases allergy-like reactions may occur, including severe reactions (shock) in very rare cases, that may need immediate medical intervention.

Mild swelling of the face, lips, tongue or throat, coughing, itching, runny nose, sneezing and hives (nettle-type rash) may be the first signs that a severe reaction is happening. Tell the mRi department staff immediately if you experience any of these signs or have difficulty in breathing.

Delayed reactions hours to days after the administration of Primovist may occur. If this should happen to you, tell your doctor or radiologist.

Problems with sense of taste

Problems with sense of smell

Flushing Blood pressure increased Breathing difficulties Vomiting Dry mouth Skin rash Severe itching* Back pain Chest pain Injection site reactions** Feeling hot Chills Tiredness Feeling abnormal

* Severe itching (Generalized itching, Itching of the eye)

** Injection site reactions (various kinds) comprise the following terms: involuntary leakage of the contrast agent and bleeding into the adjacent tissue at the injection site, Injection site burning, Injection site coldness, Injection site irritation, Injection site pain

The following side effects have been life-threatening or fatal in some cases: shock and breathing difficulties.

Changed laboratory values may occur shortly after you have been given Primovist. Therefore inform the health personnel that you have recently undergone an examination with Primovist if you take blood or urine samples.

There have been reports of nephrogenic systemic fibrosis (which causes hardening of the skin and may affect also soft tissue and internal organs) associated with use of other gadolinium-containing contrast agents.

Reporting of side effects

If you get any side effects, talk to your doctor or radiologist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

United Kingdom

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard

Malta

ADR Reporting The Medicines Authority Post-Licensing Directorate 203 Level 3, Rue D'Argens GZR-1368 Gzira

Website: www.medicinesauthority.gov.mt e-mail: postlicensing.medicinesauthority@gov.mt

5. How to store Primovist

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the vial and outer carton label after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

This medicine should be used immediately after opening.

This medicine is a clear, colourless to pale yellow solution. It should be visually inspected before use. This medicine should not be used in case of severe discolouration, the occurrence of particulate matter or a defective container.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Marketing Authorisation Holder

Bayer plc Bayer House Strawberry Hill Newbury Berkshire RG14 1JA

Manufacturer

Bayer Pharma AG Mullerstrasse 178 D- 13353 Berlin, Germany Telephone: +49 30 468- 1111

This medicine is authorised under the name Primovist in the following Member States of the EEA: Austria, Belgium, Czech Republic, Finland, Germany, Hungary, Ireland, Italy, Luxembourg, Malta, Norway, Poland, Portugal, Slovak Republic, Sweden, United Kingdom.

This leaflet was last revised in 2014-05-05

The following information is intended for healthcare professionals only:

R Renal impairment

Prior to administration of Primovist, it is recommended that all patients are screened for renal dysfunction by obtaining laboratory tests.

There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR< 30ml/min /1.73 m²). Patients undergoing liver transplantation are at particular risk since the incidence of acute renal failure is high in this group. As there is a possibility that NSF may occur with Primovist, it should therefore be avoided in patients with severe renal impairment and in patients in the perioperative liver transplantation period unless the diagnostic information is essential and not available with non-contrast enhanced MRI. If use of Primovist cannot be avoided, the dose should not exceed 0.025 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Primovist injections should not be repeated unless the interval between injections is at least 7 days.

As the renal clearance of gadoxetate may be impaired in the elderly, it is particularly important to screen patients aged 65 years and older for renal dysfunction.

Haemodialysis shortly after Primovist administration may be useful at removing Primovist from the body. There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis.

R Pregnancy and breast-feeding

Primovist should not be used during pregnancy unless the clinical condition of the woman requires use of gadoxetate.

Continuing or discontinuing breast feeding for a period of 24 hours after administration of Primovist, should be at the discretion of the doctor and lactating mother.

R Before injection

Primovist is a clear, colourless to pale yellow solution free from visible particles. The contrast medium should be inspected visually before use. Contrast media should not be used in case of severe discolouration, the occurrence of particulate matter or a defective container.

R Administration

Primovist is to be administered undiluted as an intravenous bolus injection at a flow rate of about 2 ml/sec. After the injection the intravenous cannula / line should be flushed using physiological saline solution (9 mg/ml).

P Patient should be observed for at least 30 minutes after the injection.

P Primovist must not be mixed with other medicinal products.

P Intramuscular injection must be strictly avoided.

R Handling

Primovist is ready to use.

Vials containing contrast media are not intended for the withdrawal of multiple doses. Primovist should only be drawn into the syringe immediately before use.

The rubber stopper should never be pierced more than once.

Any solution not used in one examination is to be discarded in accordance with local requirements. Further information regarding the use of Primovist is given in section 3 of the leaflet.

The peel-off tracking label on the vials should be stuck onto the patient record to enable accurate recording of the gadolinium contrast agent used. The dose used should also be recorded.

6. Contents of the pack and other information What Primovist contains

R The active substance is gadoxetate disodium. Each ml of solution for injection contains 0.25 mmol gadoxetate disodium (equivalent to 181.43 mg gadoxetate disodium).

R The other ingredients are caloxetate trisodium; trometamol, sodium hydroxide for pH adjustment, hydrochloric acid (for pH adjustment), and water for injections.

1 injection vial with 5.0ml contains 907mg gadoxetate disodium,

1 injection vial with 7.5ml contains 1361mg gadoxetate disodium,

1 injection vial with 10.0ml contains 1814mg gadoxetate disodium. What Primovist looks like and contents of the pack Primovist is a clear, colourless to pale yellow liquid free from visible particles. The contents of the packs are:

1, 5, or 10 injection vials with 5.0 ml solution for injection (in 6-ml injection vial)

1, 5, or 10 injection vials with 7.5 ml solution for injection (in 10-ml injection vial)

1, 5, or 10 injection vials with 10.0 ml solution for injection (in 10-ml injection vial)

Not all pack sizes may be marketed.

Bayer

81673632

81673632_04.indd 2